Feil Family Brain & Mind Research Institute

You are here

PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

TitlePGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.
Publication TypeJournal Article
Year of Publication2019
AuthorsLloret A, M Beal F
JournalNeurochem Res
Date Published2019 May 07
ISSN1573-6903
Abstract

In this review, we summarize the available published information on the neuroprotective effects of increasing nicotinamide adenine dinucleotide (NAD) levels in Huntington's disease models. We discuss the rationale of potential therapeutic benefit of administering nicotinamide riboside (NR), a safe and effective NAD precursor. We discuss the agonistic effect on the Sirtuin1-PGC-1α-PPAR pathway as well as Sirtuin 3, which converge in improving mitochondrial function, decreasing ROS production and ameliorating bioenergetics deficits. Also, we discuss the potential synergistic effect of increasing NAD+ combined with PARPs inhibitors, as a clinical therapeutic option not only in HD, but other neurodegenerative conditions.

DOI10.1007/s11064-019-02809-1
Alternate JournalNeurochem. Res.
PubMed ID31065944
Grant List5R01NS086746-04 / NS / NINDS NIH HHS / United States